Companies
Organon
spun out of MSD/Merck in 2021, Organon is the largest dedicated women's-health company, reporting $6.2 billion in full-year 2025 revenue and $1.91 billion adjusted EBITDA (30.7% margin), with the postpartum-haemorrhage Jada System and the Nexplanon contraceptive implant.
- Country
- United States
- Ticker
- NYSE:OGN
FDA approved
Women's health pharma
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Production site | Six manufacturing facilities located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom | sec.gov · stocktitan.net |
| Certification | GMP compliance certification for the Cramlington, UK site | cms.mhra.gov.uk · sec.gov |
| Regulatory approval | Subject to FDA and international regulatory approval for drugs and medical devices | sec.gov · stocktitan.net |
| Headcount | Over 10,000 employees worldwide as of December 31, 2025 | sec.gov · stocktitan.net |
| Revenue | $6.216 billion for full-year 2025 | organon2021tf.q4web.com · organon.com · sec.gov |
Independent sources: cms.mhra.gov.uk · sec.gov · stocktitan.net
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| FemTech biotech & women's health | regenerative-personalized | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.